Prof. Paul Parren, is an expert in antibody research, translational science and drug development. He is Exec. VP and Head of R&D at the start-up company Lava Therapeutics. He is also a biotech consultant and a professor of molecular immunology at the Leiden University Medical Center. Previously, he was head of preclinical development and research at Genmab and he was an Associate Professor at The Scripps Research Institute in La Jolla, CA. He invented and developed the approved therapeutic antibodies ofatumumab (Arzerra) and daratumumab (DARZALEX) and clinically validated antibody platform technologies for generating bispecific and enhanced-function antibodies. He received his PhD from the University of Amsterdam (1992).